Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A
Nat Rev Cancer. 2025; .
PMID: 39881005
DOI: 10.1038/s41568-024-00785-5.
Li X, Wang F, Chen K, Wu Z, Zhang R, Xiao C
J Immunother Cancer. 2025; 13(1.
PMID: 39762074
PMC: 11749649.
DOI: 10.1136/jitc-2024-010581.
Hu M, Fan D, Tu H, Tsai Y, He L, Zhou Z
Gene Ther. 2024; .
PMID: 39472678
DOI: 10.1038/s41434-024-00497-3.
Boopathy A, Nekkalapudi A, Sung J, Schulha S, Jin D, Sharma B
J Virol. 2024; 98(7):e0029424.
PMID: 38829139
PMC: 11265421.
DOI: 10.1128/jvi.00294-24.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Martinez Janez N
Cancer Med. 2024; 13(5).
PMID: 38501219
PMC: 10949085.
DOI: 10.1002/cam4.6776.
Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.
Sosa Cuevas E, Saas P, Aspord C
Cancers (Basel). 2023; 15(8).
PMID: 37190135
PMC: 10136655.
DOI: 10.3390/cancers15082206.
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.
Daly R, Scott A, Klein O, Ernst M
Mol Cancer. 2022; 21(1):189.
PMID: 36175961
PMC: 9523960.
DOI: 10.1186/s12943-022-01656-z.
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Bhardwaj N, Friedlander P, Pavlick A, Ernstoff M, Gastman B, Hanks B
Nat Cancer. 2022; 1(12):1204-1217.
PMID: 35121932
DOI: 10.1038/s43018-020-00143-y.
IL7Rα, but not Flk2, is required for hematopoietic stem cell reconstitution of tissue-resident lymphoid cells.
Worthington A, Cool T, Poscablo D, Hussaini A, Beaudin A, Forsberg E
Development. 2022; 149(8).
PMID: 35072209
PMC: 8917444.
DOI: 10.1242/dev.200139.
Regulatory T cells in ischemic stroke.
Wang H, Ye J, Cui L, Chu S, Chen N
Acta Pharmacol Sin. 2021; 43(1):1-9.
PMID: 33772140
PMC: 8724273.
DOI: 10.1038/s41401-021-00641-4.
DC-Based Vaccines for Cancer Immunotherapy.
Fu C, Zhou L, Mi Q, Jiang A
Vaccines (Basel). 2020; 8(4).
PMID: 33255895
PMC: 7712957.
DOI: 10.3390/vaccines8040706.
Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C, Peng P, Loschko J, Feng L, Pham P, Cui W
Proc Natl Acad Sci U S A. 2020; 117(38):23730-23741.
PMID: 32879009
PMC: 7519282.
DOI: 10.1073/pnas.2002345117.
Escape or Fight: Inhibitors in Hemophilia A.
Merlin S, Follenzi A
Front Immunol. 2020; 11:476.
PMID: 32265927
PMC: 7105606.
DOI: 10.3389/fimmu.2020.00476.
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Pratz K, Rudek M, Smith B, Karp J, Gojo I, DeZern A
Biol Blood Marrow Transplant. 2019; 26(2):300-306.
PMID: 31550496
PMC: 7001148.
DOI: 10.1016/j.bbmt.2019.09.023.
Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Kalathil S, Hutson A, Barbi J, Iyer R, Thanavala Y
JCI Insight. 2019; 4(15).
PMID: 31391334
PMC: 6693832.
DOI: 10.1172/jci.insight.130116.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M
Cancer Immunol Res. 2017; 5(8):676-684.
PMID: 28674082
PMC: 5547907.
DOI: 10.1158/2326-6066.CIR-17-0049.
Triptolide Upregulates Myocardial Forkhead Helix Transcription Factor p3 Expression and Attenuates Cardiac Hypertrophy.
Ding Y, Li J, Guo F, Liu Y, Tong Y, Pan X
Front Pharmacol. 2016; 7:471.
PMID: 27965581
PMC: 5127789.
DOI: 10.3389/fphar.2016.00471.
PD-1 and Foxp3 T cell reduction correlates with survival of HCC patients after sorafenib therapy.
Kalathil S, Lugade A, Miller A, Iyer R, Thanavala Y
JCI Insight. 2016; 1(11).
PMID: 27540594
PMC: 4986927.
DOI: 10.1172/jci.insight.86182.
Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation?.
Xia Y, Cai W, Thomson A, Hu X
Transl Stroke Res. 2016; 7(5):415-9.
PMID: 27307291
PMC: 5179138.
DOI: 10.1007/s12975-016-0476-4.
Immunoglobulin G promotes skin graft acceptance in an immunologically potent rat model.
Liu X, Huang T, Chen X, Yan M, Yu F, Gu H
Oncotarget. 2016; 7(26):39408-39420.
PMID: 27276685
PMC: 5129941.
DOI: 10.18632/oncotarget.9823.